<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03349606</url>
  </required_header>
  <id_info>
    <org_study_id>PRO10030625</org_study_id>
    <secondary_id>R01DA026472</secondary_id>
    <secondary_id>PRO14080588</secondary_id>
    <nct_id>NCT03349606</nct_id>
  </id_info>
  <brief_title>Cocaine Use Disorder and Cortical Dopamine</brief_title>
  <official_title>Imaging of Cortical Dopamine Transmission in Cocaine Dependence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this study is to use [C-11]FLB 457 and amphetamine (oral, 0.5 mg/kg) to measure
      cortical dopamine transmission in cocaine dependent individuals and healthy controls
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study seeks to examine dopamine (DA) transmission in vivo, using positron emission
      tomography (PET) with [C-11]FLB 457, in cortical regions of interest in subjects who have a
      history of cocaine dependence. We hypothesize that cocaine dependence is associated with
      decreases in dopamine in the prefrontal cortical regions compared to controls. This may
      explain the impulsivity and cognitive deficits that underlie relapse in this disorder.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 2, 2010</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>[C-11]FLB 457 d-amphetamine</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent change in Binding potential (BPnd)</measure>
    <time_frame>Baseline BPnd (time 0) and Post-amphetamine BPnd (time 3 hours)</time_frame>
    <description>DELTA BPnd</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Cocaine Dependence</condition>
  <arm_group>
    <arm_group_label>Cocaine dependence</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>[C-11]FLB 457 PET at baseline and post d-amphetamine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Controls</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>[C-11]FLB 457 PET at baseline and post d-amphetamine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>d-amphetamine</intervention_name>
    <description>oral d- amphetamine 0.5 mg/kg is used to stimulate dopamine release in the brain</description>
    <arm_group_label>Cocaine dependence</arm_group_label>
    <arm_group_label>Controls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>[C-11]FLB 457</intervention_name>
    <description>PET radiotracer</description>
    <arm_group_label>Cocaine dependence</arm_group_label>
    <arm_group_label>Controls</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Subjects with Cocaine Dependence INCLUSION CRITERIA

          1. Males or Females 18-40

          2. Fulfill Diagnostic and Statistical Manual (DSM-IV) Diagnosis for Cocaine Dependence

          3. Medically Healthy MAJOR EXCLUSIONS

        1. Major medical, psychiatric, co-morbid drug &amp; alcohol use disorders 2. Pregnancy or
        lactation, 3. Contraindications to MRI 4. Currently employed as radiation worker; or
        participation in radioactive drug research protocols within the previous year 5. Family
        History of a psychotic illness or manic episode in first-degree relatives

        Healthy Subjects INCLUSION CRITERIA

          1. Males or Females 18-40

          2. Absence of present or past psychiatric conditions (including alcohol or drug
             dependence)

          3. A negative urine drug screen

          4. Medically Healthy

        MAJOR EXCLUSIONS

          1. Any medical, psychiatric, co-morbid drug &amp; alcohol use disorders

          2. Pregnancy or lactation,

          3. Contraindications to MRI

          4. Currently employed as radiation worker; or participation in radioactive drug research
             protocols within the previous year

          5. Family History of a psychotic illness or manic episode, or drug and alcohol
             Abuse/Dependence in first-degree relatives
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Rajesh Narendran, MD</last_name>
    <email>narendranr@upmc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of PIttsburgh PET Facility</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rajesh Narendran</last_name>
      <email>narendranr@upmc.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 17, 2017</study_first_submitted>
  <study_first_submitted_qc>November 17, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 21, 2017</study_first_posted>
  <last_update_submitted>November 20, 2017</last_update_submitted>
  <last_update_submitted_qc>November 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>Rajesh Narendran</investigator_full_name>
    <investigator_title>Visiting Professor in Radiology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cocaine-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cocaine</mesh_term>
    <mesh_term>Amphetamine</mesh_term>
    <mesh_term>Dextroamphetamine</mesh_term>
    <mesh_term>Dopamine</mesh_term>
    <mesh_term>Dopamine Agents</mesh_term>
    <mesh_term>FLB 457</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

